Return to study ST001815 main page
MB Sample ID: SA168917
| Local Sample ID: | 11.3 |
| Subject ID: | SU001892 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 1.8 to 17 years |
| Gender: | Not applicable |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001905 |
| Treatment Summary: | Plasma samples were acquired from a single-center prospective cohort of JIA patients. The study included patients diagnosed with JIA requiring initiation of MTX for inadequately controlled disease without the need for biological therapy at initiation. Diagnosis of JIA was established based on the Edmonton 2001 International League of Associations of Rheumatology (ILAR) criteria for JIA. Patients were initiated on a standardized MTX dose of 15 mg/m2 weekly by subcutaneous or oral administration along with 1 mg folic acid daily. Concurrent medications allowed included nonsteroidal anti-inflammatory drugs (NSAIDs) and daily low-dose steroids (the lesser of 0.2 mg/kg/day or 10 mg). Intra-articular steroid injections (IASI) were allowed, however injected joints were counted as “active” at follow up to reduce the potential bias resulting from IASI. |
| Treatment Compound: | Methotrexate |
| Treatment Route: | Oral or Subcutaneous |
| Treatment Dose: | 15 mg/m^2 |
| Treatment Doseduration: | 3 months |
